Ubs Group Ag Dermata Therapeutics, Inc. Transaction History

Ubs Group Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 08, 2023	BUY	$0.18 - $184.8 $4,051 - $4.16 Million	22,510 Added 152.12%	37,308 $15,000
Q3 2022 Nov 10, 2022	BUY	$0.1 - $196.8 $359 - $706,708	3,591 Added 32.04%	14,798 $8,000
Q2 2022 Aug 10, 2022	BUY	$115.2 - $319.2 $793,036 - $2.2 Million	6,884 Added 159.24%	11,207 $7,000
Q1 2022 May 16, 2022	BUY	$223.2 - $571.2 $964,893 - $2.47 Million	4,323 New	4,323 $5,000
Q4 2021 Feb 14, 2022	SELL	$374.4 - $1500.0 $70,761 - $283,500	-189 Closed	0 $0
Q3 2021 Nov 15, 2021	BUY	$1000.8 - $1392.0 $189,151 - $263,088	189 New	189 $1,000

Ticker DRMA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 10,102,200
Market Cap $11.3M
Description
Dermata Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing pharmaceutical product candidates for the treatment of medical and aesthetic skin conditions. The company's lead product candidate is DMT310, which has completed Phase IIb clinical trial for treatment of moderate-to-severe ...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.